key: cord-0930910-gqo5it62
authors: Castiglione, Gianni M.; Zhou, Lingli; Xu, Zhenhua; Neiman, Zachary; Hung, Chien-Fu; Duh, Elia J.
title: The ancient cardioprotective mechanisms of ACE2 bestow SARS-CoV-2 with a wide host range
date: 2021-01-04
journal: bioRxiv
DOI: 10.1101/2021.01.03.425115
sha: e096f55101cc14fb82ee7a41708b34774f0855ed
doc_id: 930910
cord_uid: gqo5it62

SARS-CoV-2 infects a broader range of mammalian species than previously anticipated, suggesting there may be additional unknown hosts wherein the virus can evolve and potentially circumvent effective vaccines. We find that SARS-CoV-2 gains a wide host range by binding ACE2 sites essential for ACE2 carboxypeptidase activity. Six mutations found only in rodent species immune to SARS-CoV-2 are sufficient to abolish viral binding to human and dog ACE2. This is achieved through context-dependent mutational effects (intramolecular epistasis) conserved despite ACE2 sequence divergence between species. Across mammals, this epistasis generates sequence-function diversity, but through structures all bound by SARS-CoV-2. Mutational trajectories to the mouse conformation not bound by SARS-CoV-2 are blocked, by single mutations functionally deleterious in isolation, but compensatory in combination, explaining why human polymorphisms at these sites are virtually non-existent. Closed to humans, this path was opened to rodents via permissive cardiovascular phenotypes and ancient increases to ACE2 activity, serendipitously granting SARS-CoV-2 immunity. This reveals how ancient evolutionary trajectories are linked with unprecedented phenotypes such as COVID-19 and suggests extreme caution should be taken to monitor and prevent emerging animal reservoirs of SARS-CoV-2. One sentence summary A conserved mechanism essential for ACE2 catalytic activity is exploited by SARS-CoV-2 binding, allowing the virus to infect a wide range of species.

SARS-coronavirus-2 (SARS-CoV-2) is thought to have evolved from an ancestor 34 (RaTG13) isolated from the Chinese horseshoe bat (Rhinolophus sinicus) (1) , potentially fusing with viruses from an intermediate source (e.g. pangolin; Manis javanica) (2). These zoonotic 36 origins ultimately led to the evolution of a virus that is highly transmissible among humans, 37 causing an unprecedented public health emergency (3, 4) . A wide phylogenetic range of 38 mammalian species have been demonstrated to be susceptible to SARS-CoV-2 infection, 39 including non-human primates, dogs, cats, ferrets, hamsters and minks (5) (6) (7) (8) (9) (10) (11) (12) . Characterizing the 40 entire host range of SARS-CoV-2 is important for identifying the risks of anthroponosis and 41 zoonosis between humans and other species, which can pose a major health risk by forming 42 novel viral reservoirs where new mutations can evolve (13, 14) . A recent example is mink 43 farms, where infection by humans led to the evolution of novel viral strains, which have since 44 reinfected human populations (11). Attempts to predict the host range of SARS-CoV-2 have 45 greatly underestimated the extent to which SARS-CoV-2 can infect certain non-primate species, 46 especially non-felid carnivores including mink, dog and ferret (5) (6) (7) (8) (9) (10) (11) 15) . These predictive 47 methods depend on comparative sequence analyses of angiotensin-converting enzyme 2 (ACE2) 48 the cellular receptor for SARS-CoV-2and scoring based on sequence and structural 49 homology to the human ACE2 viral binding interface (15) (16) (17) . The difficulty of predicting the 50 SARS-CoV-2 host range through these methods proves that the virus can bind a wide-range of 51 ACE2 orthologs despite extensive sequence divergence. This opens the possibility for the 52 existence of additional unknown mammalian hosts. 53 Infection by SARS-CoV-2 is mediated by the binding of the viral S-protein receptor 54 binding domain (RBD) to ACE2 (1, 18) , displaying a nanomolar affinity higher than that of 55 (37, (39) (40) (41) . This protective role of ACE2 is largely mediated through its enzymatic processing 82 of Ang II to Ang- (1) (2) (3) (4) (5) (6) (7) , where exogenous delivery of either ACE2 or Ang-(1-7) can protect 83 against pathogenic features of multiple cardiovascular and kidney diseases (37, 41, 42) . Given 84 the myriad protective roles of ACE2 enzymatic activity, it may be expected that ACE2 function 85 is highly conserved across species. However, mice display ~ 50% higher ACE2 activity relative 86 to humans (43), and are insensitive to the vasodilatory effects of Ang-(1-7) (39), suggesting 87 increased ACE2 activity in rodents may have evolved to serve non-vasodilatory protective 88 functions. These observations suggest that minor differences in ACE2 function can drive major 89 physiological differences between species, as seen in the evolution of other protein systems (27, 90 31, 44) . Organismal sensitivity to mutations affecting ACE2 activity may be especially 91 pronounced due to the X-chromosome location of the ACE2 gene (45), where even heterozygous 92 ACE2 knockout females (-/x) display increased susceptibility to heart and kidney injury (39).

If natural variation across species has evolved to shape ACE2 function, then the sequence 94 recognized by SARS-CoV-2 may have a pleiotropic role in mediating ACE2 function. We 95 therefore investigated whether SARS-CoV-2 binding to ACE2 could be abolished without 96 disrupting ACE2 enzyme function. To expedite this, we took an evolutionary approach that 97 leveraged the natural sequence variation found in mouse ACE2, which SARS-CoV-2 is unable to 98 bind (1, 18) . Here we identify a specific combination of mutations unique to rodents which fully 99 abolishes RBD binding when inserted into human and dog ACE2, but which in isolation, 100 significantly decreases ACE2 enzyme activity. These detrimental intermediates would likely 101 severely compromise the cardio-and reno-protective functions of ACE2 activity, explaining why 102 these mutations are rare across mammalian species.

We investigated ACE2-RBD binding as well as ACE2 enzymatic function across a range 107 of boreoeutherian mammals either susceptible or immune to SARS-CoV-2 infection [human 108 (Homo sapiens), dog (Canis lupus familiaris), and pangolin (Manis javanica); vs. mouse, (Mus 109 musculus) and Chinese horseshoe bat (Rhinolophus sinicus), respectively] (1, 7, 9, 18) . Using 110 flow cytometry, we found a trend of significantly stronger association of the SARS-CoV-2 RBD 111 with both human and pangolin ACE2 relative to that of CoV-1, consistent with previous studies 112 (19) (Fig. 1A-D) . Notably, CoV-1 and -2 RBD association was strongest with human ACE2. We 113 also found evidence that the RBD of both SARS-CoV-1 and -2 S protein could not bind mouse (2, 7, 9, 18, 46) . To complement these binding assays, we 116 next characterized the ability of ACE2 orthologs to enable SARS-CoV-2 S pseudovirus entry 117 into cells. We transfected ACE2 orthologs into human cells (HEK293T) and exposed these cells 118 to pseudotyped MLV particles containing the SARS-CoV-2 S protein. Consistent with our flow 119 cytometry data and with previous studies, this assay recapitulated the host range of WT SARS-120 CoV-2 (18), displaying significant infection of cells expressing human, dog, and pangolin ACE2, 121 but not that of mouse or bat (Fig. 1E ). To investigate whether this variation in ACE2-SARS-

CoV-2 S binding is mirrored by functional variation in ACE2 enzyme activity, we measured the 123 carboxypeptidase activity of ACE2 orthologs in vitro using a well-characterized fluorometric 124 biochemical assay (43) (Materials and Methods; Fig. S1 ). Strikingly, we found significant 125 variation in ACE2 hydrolysis rates across all mammalian species, suggesting tuning of 126 enzymatic function across evolutionary history ( Fig. 1F-G To test this, we first took a bioinformatic approach. We reasoned that since ACE2 has 141 evolved under pressures related to its enzymatic processing of Ang-II/Ang-(1-7), signatures of 142 natural selection at sites within the viral binding interface may reflect a potential role of those 143 sites in mediating ACE2 catalytic activity (47). We therefore searched for shifts in ACE2 144 mutational rates (dN/dS) beyond what may be expected from neutral evolutionary pressures alone 145 (48, 49) . To do this, we constructed a phylogenetic dataset representing full-length mammalian 146 ACE2 sequences ( Fig. S2 ; Table S1 ) and conducted a codon-based statistical phylogenetic 147 analysis (PAML, HyPhy). We found significant evidence that mammalian ACE2 is under 148 positive selection, outperforming models assuming neutral molecular evolution (Table S2) . This 149 provides evidence that mammalian ACE2 functional diversification is a product of natural 150 selection, rather than neutral processes.

To focus our analysis on ACE2 sites responsible for mediating SARS-CoV-2 binding, we took 152 an evolutionary approach leveraging natural sequence variation found in mouse ACE2, which 153 SARS-CoV-2 is unable to bind (1, 18) . We identified a set of six residues unique to mouse 154 ACE2 that were of particular interest due to their proximity to viral RBD residues implicated in 155 the ACE2-RBD structure ( Fig. 2A) . These sites contact opposite ends of the viral RBD, 156 facilitating binding through a combination of hydrogen bonds (Q24, K353), as well as van der 157 Waals forces within a hydrophobic pocket of ACE2 (L79, M82, Y83, P84) (21, 23). These 158 ACE2 residues are located outside the ACE2 active site mediating catalysis of Ang-II/Ang-(1-7) 159 ( Fig. 2A ; yellow), suggesting that any role of these sites in mediating ACE2 function would 160 likely be through indirect effects modulating the protein structure, as seen in other protein 161 systems (47, 50). Through phylogenetic methods (Table S2; M8; Bayes empirical Bayes), we 162 found that several of these sites deviated significantly from neutral expectations (sites 24 ,79, 163 dN/dS>1; site 353, dN/dS<1), suggesting potential functional roles (Fig.2B) . Interestingly, these 164 sites are less variable in primates relative to other mammalian lineages ( Fig. 2B; (16)), 165 displaying significantly decreased ACE2 evolutionary rates relative to bats (Chiroptera) and 166 rodents (Table S3 ; (CmD; dN/dS). These evolutionary signatures suggest that the RBD binding 167 interface of ACE2 may play a role in the functional diversification of ACE2 catalytic activity, 168 with extant residues in primates being strongly constrained. [grey]; PAML, HyPhy) of an alignment of mammalian ACE2 coding sequences reveals positive and 175

negative selection (*) on RBD binding hotspots. Alignment of ACE2 residues across boreoeutherian 176 mammals is shown. (C) SARS-CoV-2 is unable to bind mouse ACE2, which displays unique amino acid 177 residues at positions within the RBD binding interface relative to other mammals. (D) Flow cytometry 178 was used to quantify RBD association with human cells (HEK293T) expressing WT and mutant ACE2.

(E) The effect of ACE2 mutations on ACE2 hydrolysis rates was measured using a fluorometric peptide 180

(F-G) Interaction effects between amino acids on opposite ends of the viral binding interface determine 181 RBD binding (F-G) and ACE2 activity (H-I) in both human (F, H) and dog ACE2 (G, I). 182

We next experimentally characterized the role of these sites on both SARS-CoV-1 and 183 CoV-2 binding and infection, as well as their effect on ACE2 catalytic activity. We did this by 184 substituting the rare residues found in mouse ACE2 into human and dog ACE2 (Fig. 2C) . First, 185 we characterized the role of single mutations on the binding of the SARS-CoV-1/2 S RBD to 186 human WT and mutant ACE2 using co-immunoprecipitation and flow cytometry. In contrast 187 with SARS-CoV-1 (Fig. S3 ), a single mutation was not sufficient to abolish SARS-CoV-2 RBD 188 binding to ACE2 (K353H; Fig. 2D ). Indeed, most single mutations had only minor effects on 189 SARS-CoV-2 RBD binding (Fig. 2D) . However, each of the six single mutations displayed 190 considerable effects on human ACE2 hydrolysis activity ( Fig 2E) . This demonstrates that ACE2 191 residues within the RBD binding interface can indirectly modulate ACE2 activity.

Next, we attempted to abolish RBD binding to both human and dog ACE2 by making 193 multiple substitutions at these ACE2 sites. Strikingly, RBD binding to the ACE2 of both species (Fig. 2C ). This demonstrates that SARS-CoV-2 utilizes the same combination of 201 ACE2 positions to bind both human and dog ACE2 despite amino acid variation at these sites.

This may explain why bioinformatic predictions of SARS-CoV-2 host range based on human 203 ACE2 sequence homology have tended to underestimate the infection risk of species such as 204 dogs, ferrets, and minks (6, 7, (9) (10) (11) 15) . 205 We reasoned that this could be due to conserved compensatory interactions between 206 ACE2 sites, allowing different residues to ultimately maintain the ACE2 structure bound by indicates that residues at one end of the ACE2-RBD binding cleft can modulate the structural 213 effects of residues on the other end. We hypothesized that the specific amino acid combinations 214 at these sites therefore originally evolved to maintain the ACE2 structure underpinning ACE2 215 catalytic activity. Consistent with this, we found that the detrimental functional effects of the Hence, our evidence strongly suggests that the unpredictable and wide host range of SARS-CoV-231 2 is likely due to this ancient epistasis of ACE2. constraints on protein function (31, 53). Since ACE2 activity plays major roles in the 257 cardiovascular system, we reasoned that cardiovascular differences between mammalian species 258 may result in differential constraints on ACE2 sequence-function. A central cardiovascular role 259 mediated by ACE2 activity is the regulation of blood pressure via enzymatic processing of ANG-260 (II) to ANG-(1-7) (Fig. 3B ). We found extremely low human allele frequencies for missense 261 polymorphisms at these sites (gnomAD), with most at zero (Fig.3C ). This is consistent with the 262 role of these sites in mediating ACE2 activity and with the known association of human ACE2 263 polymorphisms with hypertension (55, 56). We reasoned that these physiological constraints 264 would be more relaxed in animals with low blood pressures, permitting sequence-function 265 evolution. We conducted a phylogenetic statistical analysis on systolic blood pressure values 266 across mammalian species and observed a significant correlation with body size (r 2 =0.26; 267 p=0.001; phylogenetic independent contrast least squares linear regression) ( Fig. 3D; Fig. S6 ).

Blood pressures were lowest in rodent and bat species-two lineages immune to SARS-CoV-2 269 (18, 46) which also display the highest ACE2 evolutionary rates relative to other mammals 270 (aBsREL; Fig. 3E ; Table S2 ). This is consistent with bat (Rhinolophus sinicus) ACE2 displaying 271 the lowest hydrolysis rates relative to all other species investigated here (except Pangolin, for 272 which blood pressure measurements are not available to our knowledge). Interestingly, rodents 273 are insensitive to the vasodilatory effects of Ang-(1-7) (39), suggesting their high ACE2 activity 274 may be unrelated to low blood pressure. Although speculative, relaxed physiological constraints 275 on the vasodilatory role of ACE2 function (due to small body size) may explain why rodents 276 were situated to tolerate an evolutionary trajectory that presumably contained detrimental 277 intermediates as seen in dog and human ACE2 mutants.

An alternative explanation is that these evolutionary valleys may not exist in rodents. unique to the RBD binding domain of mice (Fig. 3G ). This strongly suggests that these 286 mutations appeared relatively recently in mouse ACE2 evolution. Since the C-terminus of 287 vertebrate ACE2 was too divergent to align, we constructed the full-length rodent ancestor 288 (RodAnc) ACE2 coding-sequence with either mouse (-M) or human (-H) C-termini, and 289 measured ACE2-specific hydrolysis activity. We found that RodAnc-M displayed high ACE2 290 hydrolysis activity indistinguishable from that of mouse, strongly suggesting that the rodent 291 ancestor had high ACE2 hydrolysis rates (Fig. 3H) . Moreover, the RodAnc with the human C-292 terminus displayed ACE2 activity significantly lower than mouse ACE2, but significantly higher 293 than that of human, suggesting the C-terminus is necessary, but not sufficient to explain the high 294 ACE2 activity seen in the RodAnc. Taken together, these results provide strong evidence that 295 mutations outside the viral binding interface of ACE2 drove increases to ACE2 carboxypeptidase 296 activity during rodent evolution. High ACE2 activity in the rodent ancestor may have therefore 297 compensated for the subsequent introduction of rare variants that are strongly deleterious 298 mutations in dog and human ACE2 backgrounds.

Discussion 301 We have shown that six mutations abolishing SARS-CoV-2 RBD-ACE2 binding also 302 individually disrupt ACE2 hydrolysis activity by up to 50-60%. This provides evidence that like 303 other proteins, the catalytic activity of ACE2 can be mediated by the indirect structural effects of 304 mutations to residues outside the active site (27, 47, 50) . Although previous work demonstrated 305 that inactivation of the ACE2 active site had no effect on SARS-CoV-1 and -2 binding, these 306 mutations were directly within the active site far from the viral binding interface (58, 59). The 307 mutations investigated here are directly within the viral binding interface of SARS-CoV-2, and 308 from species naturally immune to SARS-CoV-2 that still maintain ACE2 activity. The surprising 309 finding that mutations abolishing binding also reduce ACE2 activity is supported by the fact that 310 human ACE2 engineered to increase viral binding (T27Y, L79T, N330Y) also displays reduced 311 ACE2 activity (24). Here we discuss the implications of pervasive epistasis in ACE2 for the 312 evolution of ACE2 function, the SARS-CoV-2 host range and therapeutic design. an animal's physiology, thereby representing fitness 'peaks' in the sequence landscape (28, 31, 328 34, 53, 63-65) . Species variation in ACE2 hydrolysis rates we observed may reflect variation in 329 renin activity levels, which are a major factor in determining circulating Ang-II levels in humans 330 (39, 66, 67) . It is therefore likely that a preponderance of selective processes has shaped ACE2 331 evolution, imposed by a combination of epistatic and physiological constraints on ACE2 332 sequence-function diversification, as discussed below.

Our results strongly imply that the host range of SARS-CoV-2 may be broader than both 334 empirical and computational studies have suggested (5) (6) (7) (8) (9) (10) (11) 15) . In fact, our results suggest that 335 the SARS-CoV-2 host range among non-primate mammals may be essentially unpredictable.

This warrants extreme caution for public health efforts aiming to limit the risks of anthroponosis CoV-2 despite predictions to the contrary (6, 7, (9) (10) (11) 15 ) challenges the utility of predicting 342 infection risk from sequence homology to the human ACE2 viral binding interface (15-17). Our 343 results reconcile this apparent conundrum by demonstrating that the wide host range of SARS-

CoV-2 appears to originate from the structural effects of interacting amino acids within the 345 ACE2 viral binding interface. As in other proteins, this intramolecular epistasis makes the have been generated by the effects of population size on mutational rates. However, given the 356 physiological importance of ACE2 activity discussed above, the existence of functionally 357 detrimental intermediates may also explain why these conformations did not evolve more 358 frequently in evolutionary history (28, 31, 34, 53, 63, 64) . Our evidence suggests a confluence of 359 ancient permissive mutations and permissive cardiovascular constraints likely opened the 360 available pool of sequence variation, allowing functional and conformational diversification (25, 361 28, 29, 31). The highly effective binding mechanism of SARS-CoV-2 (21-23, 71) may therefore 362 synergize with the epistasis of the ACE2 domain to grant the virus a wide-host range-one that 363 is very difficult to predict.

Our study also has relevance for therapeutic design. Human recombinant soluble ACE2 365 (hrsACE2) is in active development as a strategy to neutralize SARS-CoV-2 by binding the viral 366 spike protein (67, 78). In human COVID-19 patients, the catalytic activity of hrsACE2 can help 367 reduce angiotensin II levels as well as inflammation associated with COVID-19, likely through M8a 0.000 [1] Supplementary Table 3 . 786 Results of Clade Model D (CmD) analyses of Mammalian ACE2 under various partitions.

1 The foreground partition is listed after the underscore for the clade models and consists of either: the clade of 'Bats, 789 'Rodents', or the clade 'Primates'. In any partitioning scheme, the entire clade was tested, and all non-foreground 790 data are present in the background partition.

2 All ΔAIC values are calculated from the lowest AIC model. The best fits are bolded with an asterisk (*).

3 ωd is the divergent site class, which has a separate value for the foreground and background partitions. 

Significance was determined through a likelihood-ratio test of null and alternative models, with reference to a χ 2 795 distribution.

Abbreviations-lnL, ln Likelihood; p, p-value; AIC, Akaike information criterion 797 798 

Analyses of selection on Mammalian ACE2 using PAML random sites models

All ΔAIC values are calculated from the lowest AIC model. The best fits are bolded with an asterisk (*)

2 ω values of each site class are shown are shown for model M0-M3 (ω0-ω2) with the proportion of each 777 site class in parentheses. For M7 and M8, the shape parameters, p and q, which describe the beta 778 distribution are listed instead. In addition, the ω value for the positively selected site class (ωp

Degrees of freedom are given in square brackets after the p-781 values. Significance was determined through a likelihood-ratio test of null and alternative models

A 193-amino acid fragment of the 825 SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

Murine Leukemia Virus (MLV)-based Coronavirus Spike-828 pseudotyped Particle Production and Infection

webPRANK: a phylogeny-aware multiple sequence aligner 830 with interactive alignment browser

New algorithms and methods to estimate maximum-likelihood 832 phylogenies: assessing the performance of PhyML 3.0

Tree of life reveals clock-like 836 speciation and diversification

FUBAR: a fast, unconstrained bayesian approximation for inferring 838 selection

W-IQ-TREE: a fast online 840 phylogenetic tool for maximum likelihood analysis

A maximum likelihood method for detecting functional 843 divergence at individual codon sites, with application to gene family evolution

The role of gravity in the evolution of mammalian blood 846 pressure

Human Ageing Genomic Resources: new and updated databases

Using the past to predict the present: Confidence intervals for 851 regression equations in phylogenetic comparative methods

Less Is More: An Adaptive Branch-Site Random Effects Model for

Efficient Detection of Episodic Diversifying Selection

The authors thank the Johns Hopkins Genetic Resources Core Facility (RRID:SCR_018669) for 606 DNA sequencing. This work was supported by research grants from the National Institutes of 

M8a 0.000 [1]